Detalle Publicación

ARTÍCULO
Measurable residual disease in multiple myeloma: ready for clinical practice?
Autores: Burgos Rodríguez, Leire; Puig, N.; Cedeña, M. T. ; Mateos, M. V.; Lahuerta, J. J.; Paiva, Bruno; San Miguel Izquierdo, Jesús (Autor de correspondencia)
Título de la revista: JOURNAL OF HEMATOLOGY AND ONCOLOGY
ISSN: 1756-8722
Volumen: 13
Número: 1
Páginas: 82
Fecha de publicación: 2020
Lugar: WOS
Resumen:
The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most accurate method to evaluate treatment efficacy. The sensitivity and standardization achieved by these techniques together with unprecedented rates of complete remission (CR) induced by new regimens, raised enormous interest in MRD as a surrogate biomarker of patients' outcome and endpoint in clinical trials. By contrast, there is reluctance and general lack of consensus on how to use MRD outside clinical trials. Here, we discuss critical aspects related with the implementation of MRD in clinical practice.